AI in Biotechnology Market worth $22,716.5 million by 2035 with 18.5% CAGR | MarketsandMarkets (TM).

Recursion Pharmaceuticals ( RXRX 1.39%) has been a pioneer in using artificial intelligence (AI) to improve the drug ...

A patchwork of internet communities is devoted to the project of ‘awakening’ more digital companions through arcane and enigmatic prompts.

AI-based drug developer Recursion’s stock barely moved Wednesday, then dropped Thursday and Friday, after reporting mixed third quarter results, setting the stage for future pipeline announcements—and ...

Abstract: The Plotkin construction combines two codes to a code of doubled length. It can be applied recursively. The class of Reed-Muller (RM) codes is a particular example. Exploiting a property of ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.34 per share a year ago. These ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious "techbio" company positions itself for its next phase of AI drug discovery.

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

SALT LAKE CITY, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding ...

Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

When I introduced Steven Pinker, it felt like our worldviews couldn't have been more different. Here's why that dissonance was exactly the point.

National Football League fans worldwide know the narrative when it comes to the Kansas City Chiefs taking on the Buffalo Bills in the regular season: the Bills come out on top. It's not like the ...